Revolution Medicines reported “unprecedented” survival results in its Phase 3 pancreatic cancer trial for daraxonrasib, triggering expectations of rapid regulatory progress. The company said the RAS-pathway inhibitor hit overall survival and progression-free survival endpoints, and that the interim analysis showed results strong enough to end the study early. Reported efficacy showed median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy in metastatic pancreatic ductal adenocarcinoma. Revolution also pointed to its FDA priority voucher status, which could accelerate U.S. review timelines once the company submits for approval. Analysts and commentators highlighted that daraxonrasib targets a RAS(ON) active-state approach, aligning with a broader shift in oncology toward subtype-specific RAS inhibition strategies rather than one-size-fits-all combinations.